Arrowstreet Capital, Limited Partnership Outlook Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

  • $108 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$0.94 - $3.31 $25,662 - $90,363
-27,300 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$0.7 - $1.58 $16,309 - $36,814
-23,300 Reduced 46.05%
27,300 $35,000
Q3 2020

Nov 12, 2020
BUY
$0.61 - $1.6 $30,866 - $80,960
50,600 New
50,600 $36,000

Others Institutions Holding OTLK

# of Institutions
6
Shares Held
66.9K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.72B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email